Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rinku Mehta

Reproductive Endocrinology Dallas, TX Medical Doctor

NPI 1871511659 CMS profile 900217

8041 Walnut Hill Ln Ste 870, Dallas, TX 75231

Open in the dashboard

General payments

$3,592

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rinku Mehta of Dallas, TX is reported in the CMS Open Payments database as having received $3,592 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $369 21
2024 General $261 18
2023 General $1,814 21
2022 General $177 2
2021 General $153 9
2020 General $242 15
2019 General $575 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rinku Mehta
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Rinku Mehta were reported at $369. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Rinku Mehta Reproductive Endocrinology median Middle half National median
2019 $575 $196 $77–$425 $163
2020 $242 $81 $35–$182 $114
2021 $153 $102 $43–$247 $132
2022 $177 $139 $62–$303 $149
2023 $1,814 $141 $65–$285 $160
2024 $261 $144 $65–$302 $164
2025 $369 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,359 6 payments
  2. Ferring Pharmaceuticals Inc. $1,354 79 payments
  3. AbbVie, Inc. $203 8 payments
  4. Vitrolife Inc. $188 1 payment
  5. CooperSurgical, Inc. $157 2 payments
  6. Organon LLC $140 8 payments
  7. EMD Serono, Inc. $99 5 payments
  8. Merck Sharp & Dohme Corporation $31 2 payments
  9. Hologic, LLC $30 2 payments
  10. Meditrina $18 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,392 112 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,200 3 payments
Products named General payments · program years 2019–2025
  1. TruClear $1,359 6 payments
  2. MENOPUR Reproductive Health $688 42 payments
  3. MENOPUR Reproductive Health $424 33 payments
  4. Orilissa $168 6 payments
  5. INVOCELL $151 2 payments
  6. FOLLISTIM AQ $97 5 payments
  7. GANIRELIX ACETATE $88 4 payments
  8. PREGNYL $88 4 payments
  9. IVF Products $81 1 payment
  10. STRIPPER $77 1 payment
  11. Other $194 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record